STADA Arzneimittel AG / Preliminary Results/Forecast
28.07.2008
Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Today, on July 28, 2008, the Executive Board of STADA Arzneimittel AG,
during an Executive Board meeting, put the Groups growth expectations for
the current fiscal year in more concrete terms.
The basis for this was the preliminary results of the first half year of
2008. According to these figures, in the first half STADA increased sales
presumably by approx. 12% to approx. EUR 822.8 million (first half of 2007:
EUR 737.4 million) and net income by approx. 11% to approx. EUR 64.7
million (first half of 2007: EUR 58.3 million). Net income adjusted for
one-time special effects for the first six months of 2008 will presumably
grow by approx. 14% to approx. EUR 67.2 million (first half of 2007: EUR
59.2 million).
Thus, STADA was presumably once again able regardless of difficult
conditions in numerous national markets characterized by regulation and
competition such as Germany, Belgium, Great Britain and Spain to increase
sales and net income by double digit percentage points in the first six
months of 2008. Against the backdrop of these difficult conditions, growth
achieved is satisfactory. The final results for the first half of 2008 will
be published on August 13, 2008.
In the outlook, the Executive Board assumes that the business trends will
recover in several national markets as compared to the first half of 2008,
but that overall the Groups business results in the second half of 2008
will be characterized by a subdued growth dynamic particularly compared
to the operationally very good second half of 2007.
Against this backdrop the Executive Board expects, from todays
perspective, once again clear sales growth within the Group for fiscal year
2008; it is unclear, however, whether the growth rate will again be in the
double digit percentage range.
In terms of earnings, the Executive Board assumes, from todays
perspective, that net income 2008 will again show clear double-digit
percentage growth as compared to net income 2007 (EUR 105.1 million) which
was burdened by high one-time special effects; the earnings level adjusted
for special effects of the previous year (adjusted net income 2007: EUR
146.8 million) will, however, probably not be achieved in fiscal year 2008.
The Executive Board has reacted to the subdued growth dynamic through
operative measures. Thus, various Group units will be realigned in terms of
sales and the Groups objectives for continuous cost optimization will be
revised. In addition, suitable acquisition objects will continue to be
sought. Against this backdrop, from todays perspective STADAs Executive
Board is optimistic that STADA, despite conditions that remain challenging,
will once again achieve significant growth in sales and earnings in the
years to come.
Further information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 218 /
61118 Bad Vilbel, Germany /
Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 /
E-mail: communications@stada.de
Or visit our website at www.stada.com
DGAP 28.07.2008
---------------------------------------------------------------------------
Language: English
Issuer: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Deutschland
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf;
Freiverkehr in Berlin, Hannover, Hamburg, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: STADA: Satisfactory growth in H1/2008 outlook: subdued growth dynamic
| Quelle: EQS Group AG